Frohlich Tom
SEC CIK 1823925 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| JBIO | Jade Biosciences, Inc. | CEO, Dir | 86.3K | $44.4K | — | 2 | 2025-05-16 | 2026-02-12 |
Most active insiders at JBIO, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Balta Elizabeth | See Remarks | — | — |
| 2 | Frohlich Tom | CEO, Dir | — | — |
| 3 | King Andrew James | See Remarks | — | — |
| 4 | Dahms Bradford D. | CFO | — | — |
| 5 | Fairmount Healthcare Fund II L.P. | Dir, 10% | — | — |
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-13 | 2026-02-12 | JBIO | Jade Biosciences, Inc. | Frohlich Tom | CEO, Dir | A - Grant | $0.00 | +78.8K | 86.3K | +1,039% | $0 |
| 2025-05-19 | 2025-05-16 | JBIO | Jade Biosciences, Inc. | Frohlich Tom | CEO, Dir | P - Purchase | $7.40 | +6,000 | 6,000 | New | +$44.4K |
Purchase Sale Sale after option exercise All abbreviations